"Dahlöf B" - Selaus tekijän mukaan Kansanterveyslaitos KTL
-
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S; LIFE Study Group; Tuomilehto J; Sarti C
Lancet (2002) -
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; for the LIFE Study Group; Tuomilehto J; Sarti C; Ylihärsilä H
Lancet : 9311 (2002) -
Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study
Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; LIFE Study Group; Tuomilehto J; Sarti C
Hypertension (1998) -
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA)
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B; on begalf of the ASCOT investigators (Tuomilehto J; Valle T)
European Journal of Cardiovascular Prevention and Rehabilitation (2005) -
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients. The Losartan Intervention For Endpoints (LIFE). Reduction in Hypertension Study
Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B; LIFE Study Group; Sarti C; Tuomilehto J
Hypertension (2000) -
Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarthan Intervention For Endpoint Reduction (LIFE) Substudy
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H; for the LIFE Study Group; Sarti C; Tuomilehto J; Ylihärsilä H
JAMA (2003) -
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE Study
Wachtell K; Bella JN; Liebson PR; Gerdts E; Dahlöf B; Aalto T; Roman MJ; Papademetriou V; Ibsen H; Rokkedal J; Devereux RB; Sarti C; Tuomilehto J
Hypertension (2000) -
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Östergren J; ASCOT Investigators; Sarti C; Tuomilehto J; Valle T
Lancet (2003) -
Rationale, design, methods and baseline demography of participants of th Anglo-Scandinavian Cardiac Outcomes Trial
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; The ASCOT investigators; Sarti C; Tuomilehto J; Valle T
J Hypertens : 6 (2001) -
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)
Sever PS; Poulter NR; Dahlöf B; Wedel H; Collins R; Beevers G; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; Östergren J; (Tuomilehto J; Valle T)
Diabetes Care (2005) -
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)
Poulter NR; Wedel H; Dahlöf B; Sever PS; Beevers DG; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; Östergren J; Pocock S; for the ASCOT Investigators; (Tuomilehto J)
Lancet (2005) -
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
Hoieggen A; Alderman MH; Kjeldsen SE; Julius S; Devereux RB; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederball-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Chen C; Dahlöf B; LIFE Study Group; Sarti C; Tuomilehto J; Ylihärsilä H
Kidney Int (2004) -
The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, Design and Methods
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; The LIFE Study Group; Tuomilehto J; Sarti C
AM J HYPERTENS : 7 (1997)